News
How Long Do You Want to Live? Age-Reversing Injection
| In a world first, a human has received a cellular reprogramming injection, biotechnology company Life Biosciences announced yesterday. The experimental treatment will be tested in close to 20 patients with glaucoma or nonarteritic anterior ischemic optic neuropathy. The gene therapy involves returning cells to their younger states so they can become resilient to disease, but not all the way to their newborn stem cell state. The company has successfully reversed tissue aging in monkeys and mice using this method, including healing age-related blindness. However, researchers are concerned about the possibility of side effects in humans, as two of the four proteins involved in the process have the potential to divide uncontrollably (in animal trials, some mice developed tumors). For the first-ever human trial, researchers are injecting the therapy into a glaucoma patient’s eye and will monitor the intervention for six months. Ultimately, researchers hope to expand interventions into liver and muscle cells, with Jeff Bezos and Sam Altman backing some of Life Biosciences’ competitors (see more via YouTube). |



